Home → Focus

Sponsor Story Board Print E-mail
Written by Vitale Health Law   
Tuesday, 20 June 2017 00:00

   vitale 25yearsad approved jan 23 2014
Last Updated on Monday, 19 June 2017 17:55
Steve Scalise's Doctor On Congressman's Condition, Injuries Sustained Print E-mail
Written by FHI's Week in Review   
Monday, 19 June 2017 17:53

Dr. John Torres has an exclusive interview with Dr. Jack Sava (director of trauma at the MedStar Washington Hospital Center) about Rep. Steve Scalise's condition, what's being done to treat him and Scalise's chances for recovery. This video was posted to YouTube by NBC on 6.16.17...

Read more in the current issue of Week in Review>>

Last Updated on Tuesday, 20 June 2017 13:47
NEJM Offers Bleak Assessment of Global Obesity Situation Print E-mail
Written by Jeffrey Herschler   
Friday, 16 June 2017 16:48

Entitled Health Effects of Overweight and Obesity in 195 Countries over 25 Years and posted to the New England Journal of Medicine on 6.12.17, the authors offered the following depressing statistics and insights:
  • The prevalence of obesity among children and adults has doubled in 73 countries since 1980 and has shown a continuous increase in most other countries.
  • Epidemiologic studies have identified high body-mass index as a risk factor for an expanding set of chronic diseases.
  • In 2015, high BMI contributed to 4.0 million deaths, which represented 7.1% of the deaths from any cause.
In recent years, some countries have started to implement a range of interventions to reduce obesity, but no major population success has yet been shown.

Last Updated on Tuesday, 20 June 2017 13:45
FDA Approves First Generic Truvada in U.S. Print E-mail
Written by FHI's Week in Review   
Sunday, 11 June 2017 15:30

Robert Lowes delivers news (login/complimentary subscription required) from the FDA on June 09, 2017:

The U.S. Food and Drug Administration (FDA) has approved the first generic version of emtricitabine/tenofovir disoproxil (Truvada, Gilead Sciences) to both treat and prevent HIV infections in this country, the agency announced today.

According to Mr. Lowes:

The list price for Gilead Science's Truvada is roughly $1500 for a month's regimen of one pill per day, or about $18,000 a year, although health insurance and patient-assistance programs knock down the price considerably. Generic versions of Truvada in other countries cost as little as $70 a year, according to Mitchell Warren, executive director of AVAC, an international organization that promotes HIV prevention.

Read more in the current issue of Week in Review>>

Last Updated on Monday, 12 June 2017 15:34
Primary Care Offers on the Rise, Including Salary and Signing Bonuses Print E-mail
Written by FHI's Week in Review   
Monday, 29 May 2017 13:34

The Medicus Firm, a national physician search firm headquartered in Dallas, released its 2nd annual primary care and advanced practice placement compensation summary report May 23, 2017.

According to the report, average total compensation packages offered to primary care physicians, including signing bonus, increased from $226,755 in 2015, to $257,533 in 2016. This includes family medicine physicians and internal medicine physicians in communities of all sizes, across the country.

Read more in the current issue of Week in Review>>

Last Updated on Friday, 16 June 2017 16:47
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 108

Website design, development, and hosting provided by